RadPharm, Inc. an Imaging Core Laboratory and Medifacts International, Inc, a Cardiovascular Core Laboratory announced the merger of their business operations. The combined company will be named CoreLab Partners (“CoreLabs”) and will have its corporate headquarters in Princeton, New Jersey.
The combination of RadPharm and Medifacts creates one of the largest independent core labs serving the market. The CoreLabs global footprint comprises more than 400 employees and includes offices with operational capabilities in North America, Europe, and Asia. The company has leveraged this worldwide infrastructure to support over 100 sponsors, including a wide range of pharmaceutical, biotech, medical device and contract research organizations, and more than 450 clinical trials in 60 countries.
RadPharm and Medifacts address distinctive, attractive segments of the pharmaceutical outsourcing market through a complementary core lab business model. Oncology and Cardiovascular drug programs are two of the highest growth segments of the clinical trials services market. CoreLabs will offer drug sponsors and their CRO partners a much deeper suite of cost effective services solutions across a substantially broader range of modalities and therapeutic indications.
Commenting on the merger, Michael Woehler, PhD, President and Chief Executive Officer of CoreLab Partners, said, “As they seek to gain cost advantages over their competitors, drug development companies and contract research organizations continue to shift their paradigm by streamlining their outsourcing functions and partnering with a smaller universe of key vendor relationships. I am confident that the financial scale and organizational strength of the combined RadPharm and Medifacts teams will provide our clients with the comfort of knowing that their clinical trials will be completed on-time, without interruption, at the highest levels of quality and efficiency.” Woehler continued, “Pharmaceutical and biotech companies today are seeking strategic partnerships with vendors who can be trusted to deliver high quality service and who have experience in getting drugs approved by regulatory agencies around the world. CoreLab Partners brings together two teams with focused, global capabilities and proven track records of operational excellence and therapeutic expertise.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.